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Background: Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers.
The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose
and treat at early stages. Currently approved second-line treatments following surgical resection of MMs include a
combination of cisplatin or carboplatin (delivered systemically) and pemetrexed, a folate inhibitor, with or without
subsequent radiation. The systemic toxicities of these treatments emphasize the need for more effective, localized
treatment regimens.
Methods: Acid-prepared mesoporous silica (APMS) microparticles were loaded with doxorubicin (DOX) and
modified externally with a mesothelin (MB) specific antibody before repeated intraperitoneal (IP) injections into a
mouse xenograft model of human peritoneal MM. The health/weight of mice, tumor volume/weight, tumor
necrosis and cell proliferation were evaluated in tumor-bearing mice receiving saline, DOX high (0.2 mg/kg), DOX
low (0.05 mg/kg), APMS-MB, or APMS-MB-DOX (0.05 mg/kg) in saline.
Results: Targeted therapy (APMS-MB-DOX at 0.05 mg/kg) was more effective than DOX low (0.05 mg/kg) and less
toxic than treatment with DOX high (0.2 mg/kg). It also resulted in the reduction of tumor volume without loss of
animal health and weight, and significantly decreased tumor cell proliferation. High pressure liquid chromatography
(HPLC) of tumor tissue confirmed that APMS-MB-DOX particles delivered DOX to target tissue.
Conclusions: Data suggest that targeted therapy results in greater chemotherapeutic efficacy with fewer adverse
side effects than administration of DOX alone. Targeted microparticles are an attractive option for localized drug
delivery.
Keywords: Targeted therapy, Mesoporous silica, Peritoneum, Chemotherapy, Microparticles* Correspondence: brooke.mossman@uvm.edu
1Department of Pathology, University of Vermont College of Medicine, 89
Beaumont Avenue, Burlington, VT 05405-0068, USA
Full list of author information is available at the end of the article
© 2013 Macura et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Macura et al. BMC Cancer 2013, 13:400 Page 2 of 14
http://www.biomedcentral.com/1471-2407/13/400Background
Malignant mesothelioma (MM) is an aggressive tumor
of mesothelial cell origin and is often associated with
occupational exposures to asbestos fibers [1-3]. MM pre-
dominantly develops in the pleural and peritoneal cav-
ities, and tumors often spread diffusely throughout these
cavities before a diagnosis is made in late stages of
tumor development. Current therapies for MM include
resection by surgery, systemic chemotherapy, gene ther-
apy, immunotherapy, radiation, and palliative procedures
[4]. The limited response and deleterious effects of
current treatment therapies demand the development of
novel therapeutic strategies to decrease the systemic tox-
icity of chemotherapeutic agents and specifically target
MMs. Intraperitoneally (IP) delivered chemotherapeutics
following tumor resection is an actively explored ap-
proach to decrease systemic toxicity and enhance the
uptake of chemotherapeutic drugs [5,6]. It has recently
been reported that patients who were administered
hyperthermic IP chemotherapy (DOX in combination
with cisplatin) following surgical debulking of peritoneal
MMs had an increased 5 year survival rate of 29-63%
[7]. Peritoneal MMs are of unique importance because
of their increasing prevalence in younger adults often
without obvious exposure to asbestos [8].
Effective treatment of MM remains an unmet clinical
need. We have previously characterized an IP model of
MM in severe combined immunodeficient (SCID) mice
[9], and have evaluated the potential of acid-prepared
mesoporous silica particles (APMS) for their ability to
target and be retained by spheroid and mesenteric MMs
in vivo following modification with an antibody specific
to human mesothelin (APMS-MB) [10]. APMS micro-
particles (patented by Christopher C. Landry at the Uni-
versity of Vermont) are amorphous silica particles (1-2
μm diameter) with a disordered pore structure, a large
specific surface area, and a large pore volume [11]. Char-
acteristics such as tunable particle diameter and pore
size, the large internal surface area, and the ability to
functionalize the external surfaces of APMS with
tetraethylene glycol (TEG) or antibodies to facilitate
targeting and uptake of the particles by cells, make
APMS an optimal delivery agent for chemotherapeutic
agents, DNA plasmids, siRNA, or other macromolecules
[12-14]. Additionally, amorphous silicas produce no
chronic adverse biological responses [15]. Recently we
have shown that APMS-injected IP penetrate to the in-
terior of MMs over time without changes in immune
profiles in peritoneal lavage fluid (PLF) [10].
In this study, we targeted particles to MM using an
antibody for mesothelin, a 40 kD glycophosphatidylinosi-
tol-anchored glycoprotein on the cell surface that nor-
mally functions in cell-to-cell adhesion [16]. Mesothelin
is a differentiation antigen with expression normallylimited to mesothelial cells lining the pleura, pericar-
dium, and peritoneum [16,17]. However, mesothelin is
over-expressed in several human cancers including virtual-
ly all MMs, ovarian cancers (70% of cases), lung cancers
(50% of cases), and pancreatic/biliary adenocarcinomas
[18-22]. The 71 kD protein encoded by the mesothelin
gene is further processed to a 31 kD protein, megakaryo-
cyte potentiating factor, which is released into serum
[18,19,23]. The expression of mesothelin in the serum of
MM patients results in the production of mesothelin-
specific immunoglobulin G (IgG) antibodies, enabling a
protective, host humoral immune response [20].
After IP injection, APMS functionalized with an
antibody specific to the membrane-bound mesothelin
protein (APMS-MB) are more readily taken up, internal-
ized, and retained by MMs over time when compared to
non-antibody functionalized APMS [10]. Particle uptake
by major organs is low compared to tumor uptake when
examined by inductively coupled plasma mass spectrom-
etry (ICP-MS) or scanning electron microscopy and
energy dispersive spectroscopy. Moreover, we have char-
acterized urinary clearance patterns using gadolinium-
labeled APMS in healthy rats [24] as well as selective
and active uptake of APMS functionalized with a num-
ber of moieties, including TEG, fluorophores, and
targeting antibodies in mesothelial and mesothelioma
cells in vitro [12-14]. Based on results of studies demon-
strating that APMS do not elicit toxicity nor immune re-
sponses after intrapleural or IP injections [10,14], we
hypothesized that targeted APMS-MB loaded internally
with DOX (APMS-MB-DOX) would inhibit MM devel-
opment and growth more effectively than DOX alone. In
studies here, we demonstrate the efficacy of this ap-
proach and examine the effects of this strategy on tumor
volume and weight, animal weight and health, tumor cell
necrosis and proliferation, and changes in inflammatory
cell profiles in PLF. Our findings are not only relevant to
MM, but also to treatment of other intracavitary tumors
(ovarian, pancreatic) that over-express mesothelin.Methods
Cells and cell culture
The HMESO MM line was previously described [25]
and obtained from Joseph R. Testa (Fox Chase Cancer
Center, Philadelphia PA). HMESO cells were maintained
in Dulbecco’s Modified Eagle Medium DMEM/F12 50/
50 (Mediatech, Manassas, VA) supplemented with 10%
fetal bovine serum (FBS), 0.1 μg/mL hydrocortisone
(Sigma, St. Louis, MO), 2.5 μg/mL insulin, 2.5 μg/mL
transferrin, 2.5 ng/mL sodium selenite (Sigma, St. Louis,
MO) and penicillin-streptomycin (50 U/mL penicillin G,
50 μg/mL streptomycin sulfate) (Invitrogen, Carlsbad,
CA) [26]. Cells were maintained at 37°C in 5% CO2.
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and subsequent modifications
Porous, amorphous silica microparticles (APMS) pre-
modified with TEG on their external surfaces [11], were
used for subsequent modifications in experiments de-
scribed here [13]. APMS microparticles were modified
using an antibody to mesothelin (MB) and loaded with
DOX as previously described [13,24].
SCID mouse xenograft model of human malignant
mesothelioma
The SCID mouse xenograft model has been previously
described [9,26]. Figure 1 shows the treatment regimen
employed here. Groups consisted of mice receiving sa-
line (0.9% NaCl {pH 7.4}), APMS-MB (no DOX), DOX
high (0.2 mg/kg), DOX low (0.05 mg/kg), or APMS-MB-
DOX (0.05 mg/kg) (n = 6 mice/treatment group). In
brief, 1 × 106 HMESO cells (in 50 μL sterile 0.9% NaCl
{pH 7.4}) were injected IP into each mouse. All mice
were weighed 3×/wk for 4 wks prior to treatments. Both
free-floating spheroid and mesenteric tumors lining theFigure 1 Model of MM tumor induction and targeted chemotherapy
protocol. Tumor formation was achieved by a single IP injection of MM (1
Mice were weighed every 3-4 days. The treatment groups included IP injec
(0.05 mg/kg), APMS-MB loaded with DOX at equivalent low dose (0.05 mg
3× per wk for 3 wks). Mice were euthanized after a total of 8 treatment inj
(N = 6 mice/group). Two mice in the saline group did not develop tumorsdiaphragm develop at 4 wks in all mice [9], at which
time IP treatments were initiated. Mice were weighed on
each treatment day prior to injection to enable the ad-
justment of dose per individual body weight. All animal
procedures were approved by the University of Vermont
IACUC committee.
Measurement of tumor weight and volume
Mesenteric and spheroid tumors from treated mice were
weighed and measured using digital calipers following
euthanasia and resection. Free-floating spheroid tumors
were weighed individually if possible, but in cases where
spheroids were too small, all the spheroids (< 1 mm3)
for an individual animal were pooled and measured as
one mass. Tumor volumes were calculated following the
formula (l × w × h × pi/6). The average tumor volume
and weight per mouse was then calculated for each
treatment group. We also evaluated the percentage dis-
tribution of tumors at different sites (Table 1). Gross
examination of tumors and major organs was performed
following euthanasia.in SCID mice. A schematic overview of the MM tumor induction
× 106 cells) followed by a 4 wk latency period to allow tumor growth.
tions of saline (500 μL), APMS-MB (no DOX), DOX at a low dose
/kg), and DOX at a high dose (0.2 mg/kg) (all in saline at 500 μL,
ections due to the morbidity and weight loss in the DOX high group
, thus N = 4 in subsequent analysis of data.
Table 1 Percent (%) MM tumor distributiona
Saline APMS-MB DOX low (0.05mg/kg) APMS-MB-DOX (0.05mg/kg) DOX high (0.2 mg/kg)
Injection site 4.17 2.38 4.17 5.56 0.00
Pleura 0.00 0.00 3.33 0.00 0.00
Diaphragm 4.76 0.00 0.00 0.00 0.00
Esophagus 0.00 0.00 0.00 2.78 2.38
Liver 10.91 5.16 2.78 4.86 11.62
Kidney 4.44 3.97 6.11 9.33 8.49
Gut 8.33 19.60 12.36 15.56 4.17
Stomach 11.67 13.10 18.06 15.63 7.45
Spleen 4.52 14.21 11.25 20.38 7.04
Intestine 26.43 28.89 25.00 14.64 36.47
Bladder 0.00 0.00 0.00 0.00 2.78
Ovaries/Testes/Vas deferens 24.76 12.70 16.94 11.27 19.60
aAs measured by the average percent (%), per treatment group, of the number tumors recovered found attached to or adjacent to respective organs and areas.
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Mesenteric and spheroid tumors collected from saline
controls and animals treated with DOX low (0.05 mg/kg)
or APMS-MB-DOX (0.05 mg/kg) were preserved in
4% paraformaldehyde, paraffin embedded, and processed
for hematoxylin and eosin (H&E) staining. Processing
and sectioning (4 μm) of tissues was performed in
the Department of Pathology (Fletcher Allen Health Care,
Burlington, VT). Staining of tissues using H&E was
performed following standard protocols [27], and MM
tissue sections were examined for necrosis by a board-
certified pathologist (KJB). Images were captured using
an Olympus BX50 upright light microscope (Olympus
America, Lake Success, NY) with an attached Q Imaging
Retiga 2000R digital CCD camera (Advanced Imaging
Concepts, Inc., Princeton, NJ).
Ki-67 immunohistochemistry and quantification
Mesenteric and spheroid tumor sections were de-
paraffinized in xylenes (2 × 15 min) and rehydrated to
ddH2O through a graded series of ethanol (100% to 50%).
Staining of tissues for Ki-67 as a marker of proliferation
was performed following standard protocols as previously
described [28]. The monoclonal mouse anti-Human Ki-67
primary antibody (Vector Laboratories, Burlingame, CA,
and Leica Microsystems, Buffalo Grove, IL) (1:25 in 1%
bovine serum albumin (BSA) in 1× phosphate buffered
saline (PBS)) was used [29]. Slides were then dehydrated
by dipping them in 100% ethanol (5×) twice, xylenes (5×),
and then allowed to air dry before they were coverslipped
using Permaslip® (American MasterTech, Lodi, CA) as
the mounting agent. Cell proliferation, measured as
the percentage of Ki-67 positive cells was quantitated
by counting the number of Ki-67 positive (brown nuclei)
and negative (purple nuclei) tumor cells, in 5 randomKi-67 expressing regions consisting of 200 cells each.
Representative images were captured using an Olympus
BX50 upright light microscope (Olympus America, Lake
Success, NY) with an attached Q Imaging Retiga 2000R
digital CCD camera (Advanced Imaging Concepts, Inc.,
Princeton, NJ).
Staining for M1 and M2 tumor-associated macrophages
(TAMs)
To determine patterns of populations of TAMs associ-
ated with tumor masses, slides cut from frozen OCT
blocks of saline and APMS-MB groups were fixed in
acetone for 15 min and stained as described previously
(10), but using the primary antibodies, rabbit anti-mouse
NOS II (1:1000 dilution) for M1 TAMs and rat anti-
mouse CD206 (1:200 dilution) for M2 TAMs. Both
antibodies were from AbD, Serotec (Raleigh, NC). The
secondary antibodies used were goat anti-rabbit Alexa
555 and goat anti-rat Alexa 488. Both secondary
antibodies were diluted 1:500 and purchased from
Invitrogen (Carlsbad, CA). Nuclei were stained with
4,′6-diamidino-2-phenylindole (DAPI) (1:200 dilution).
All antibody and DAPI dilutions were in PBS/1% BSA.
Slides were coverslipped as described previously (10)
and examined with a confocal laser scanning microscope
(CLSM) Zeiss 510 META (Thornwood, NY). Tiled im-
ages (5 images × 5 images) were used to assess profiles
of TAMs in whole MMs, and representative areas were
examined at higher magnifications (10).
Collection of PLF samples from SCID mice and
preparation of cytospins
Mice were euthanized with 0.1 mL of Sleep Away (26%
sodium pentobarbital, Webster Veterinary) before 5 mL
of cold phosphate buffered saline (PBS) (Ca/Mg-free)
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using an 18 gauge needle. The abdomen was then lightly
massaged, and the PBS removed. PLF was centrifuged,
and cell free supernatant was stored at -80°C. Total
white blood cell counts in PLF were assessed manually
using a hemocytometer. Cytospins were prepared from
50,000 cells following standard protocols [14,26] and
were stained using a HEMA 3 kit (Fisher Scientific,
Middletown, VA) per the manufacturer instructions.
Three hundred cells per slide were counted by two indi-
viduals. The counts were then averaged, and the per-
centages of each cell type and total numbers were used
to calculate the total numbers of cell type/mL for each
animal in each treatment group.
Determination of DOX concentrations in PLF using high
pressure liquid chromatography (HPLC)
After collection of PLF fluid as previously described
[9], PLF samples (500 μL) from the saline, DOX low
(0.05 mg/kg) and APMS-MB-DOX (0.05 mg/kg) treat-
ment groups were centrifuged at 10,000 × g at 4°C
for 5 min. The supernatant was transferred to a fresh
Eppendorf vial, and a daunorubicin internal control (final
concentration 1 μM) was added to samples. Samples were
then vortexed briefly and incubated at 37°C for 15 min
in the dark. Proteins were precipitated from PLF sam-
ples by adding 250 μL of acetone and 50 μL of aqueous
ZnSO4 solution (400 mg/mL) followed by vortexing.
Samples were then centrifuged at 20,000 × g (10 min)
at 4°C, and the supernatants were transferred to new
vials, and dried under a fume hood in a heat block (65°C)
under a stream of nitrogen. The residue was solubilized in
1 mL of methanol, and 200 μL of sample was used for
HPLC analysis.
Determination of DOX concentration in tumor tissue
using HPLC analysis
A section of tumor tissue from one tumor/animal from
the saline, DOX low (0.05 mg/kg) and APMS-MB-DOX
(0.05 mg/kg) treatment groups was removed, and the
wet weight recorded. The tissue was then placed in a vial
of 380 μL PBS, and 10 μL of lysis solution (Triton X-
100, 3% final concentration) was added. Tissue was
homogenized using a Biospec Tissue-Tearor (Biospec
Products, Racine, WI). Ten μL of Proteinase K (10 mg/
mL) was added to the homogenized tissue followed by
incubation for 45 min in a water bath at 65°C. The in-
ternal standard, daunorubicin, was added to each sample
(112.8 μL of 10 μg/mL solution), and samples were
brought to a final volume of 800 μL with 1 × PBS. Ten
μL of phenylmethylsulfonyl fluoride was added to sam-
ples for 10 min. Twenty μL MgCl2 (0.4 M) and 40 μL
DNase I (1 mg/mL) were then added, and samples were
centrifuged (10,000 × g) for 5 min at 4°C followed byincubation in a water bath at 37°C for 30 min. Following
incubation, 450 μL of each sample was added to 450 μL
methanol and 45 μL ZnSO4 (400 mg/mL), vortexed, and
centrifuged (10,000 × g) for 5 min at 4°C, whereupon
200 μL was used for HPLC analysis.
HPLC
The HPLC method for detection of DOX described
previously [9,30] was followed for the analysis of all
samples.
Statistical analysis
The General Linear Models procedure (PROC GLM) of
the SAS System for Windows was used for statistical
analysis of data. All data (excluding the analysis of
weights over time) were evaluated primarily by one way
analysis of variance (ANOVA) followed by Fisher’s LSD
pairwise tests for adjustment of multiple pair-wise com-
parisons between treatment groups. For the weights
across time data, a repeated measures analysis of vari-
ance was performed on mouse weights to compare the
rate of weight loss among treatment groups. Statistical
significance was determined as p ≤ 0.05.
Results
Tumor volume is significantly decreased after treatment
with APMS-MB-DOX (0.05 mg/kg) in contrast to DOX
(0.05 mg/kg) alone or saline controls
We hypothesized that targeted treatment using APMS-
MB-DOX would reduce MM tumor volume and weight
more effectively than the same dose of DOX adminis-
tered alone in an established IP xenograft model [9,26]
(Figure 1). After 3 wks of treatment, we observed that
mice receiving IP injections of DOX at 0.2 mg/kg (high
concentration) had significantly reduced tumor volumes
(p ≤ 0.05) compared to saline treated mice, those receiv-
ing DOX at 0.05 mg/kg (low concentration), or those
receiving APMS-MB without DOX (Figure 2A). Mice
receiving APMS-MB-DOX at 0.05 mg/kg also showed
reduced tumor volume compared to the same groups
(p ≤ 0.05). Consistent with these results, average
tumor weight was significantly reduced (p ≤ 0.05) in
the DOX high (0.2 mg/kg) and the APMS-MB-DOX
low (0.05 mg/kg) groups when compared to saline
controls. Treatment with DOX (0.05 mg/kg) alone, or
APMS-MB groups did not have an effect on tumor
weight in comparison to saline controls (Figure 2B).
These results demonstrate that treatment with APMS-
MB-DOX (0.05 mg/kg) significantly reduces tumor
weight in contrast to the DOX (0.05 mg/kg) group
alone. Moreover, they suggest that changes in tumor
weight and volume are due to more efficient delivery
of DOX and not due to the particles (APMS-MB) them-
selves. In addition, we evaluated the distribution of MMs
Figure 2 Treatment with APMS-MB-DOX microparticles (0.05
mg/kg) significantly reduces tumor volume and weight. (A) The
average tumor volume (mm3), including pooled spheroids, per
treatment group is provided (Mean +/- SEM). Treatment with DOX
at high concentrations (0.2 mg/kg) or APMS-MB-DOX (0.05 mg/kg)
significantly reduced the average tumor volume/mouse compared
to saline (*) and APMS-MB (†) controls (p ≤ 0.05). (B) The average
tumor weight (gm) is represented for each treatment group
(Mean +/- SEM). Treatment with DOX high (0.2 mg/kg) significantly
reduced the average tumor weight/mouse compared to saline (*)
and APMS-MB (†) controls (p ≤ 0.05). Treatment with APMS-MB-DOX
(0.05 mg/kg) significantly reduced tumor weight in comparison to
the APMS-MB group (†).
Figure 3 Treatment with DOX high (0.2 mg/kg) causes toxicity
and weight loss. Mice were weighed prior to each treatment.
(A) Weights are plotted as the mean group weight (gram) at each
treatment time point. Differences in the slope of average weights
over time in the DOX high (0.2 mg/kg) treatment group were
significantly lower (*) (p ≤ 0.05) in comparison to all other treatment
groups. No significant differences in weight were found between all
other treatment groups. (B) SEM ranges for each treatment group
over time are provided.
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studies revealed that the vast majority of tumor metas-
tases occurred in the intestines or ovaries/testes (approxi-
mately 25% of MMs at each site) in untreated (saline
control) mice. These numbers were reduced most dra-
matically (15 and 11%, respectively) in the APMS-MB-
DOX (0.05 mg/kg) group.Weight loss associated with high DOX therapy (0.2 mg/kg)
is not observed at effective APMS-MB-DOX (0.05 mg/kg)
concentrations
Once tumors become large (> 2.0 cm3), MM-bearing
mice rapidly lose weight, become lethargic, and cease
normal grooming behavior. We hypothesized that modi-
fication of the APMS microparticles with a targeting MB
would increase drug delivery to tumor tissues and
decrease DOX-related weight loss. The weights of mice
used in this study were measured throughout the
experiment. Indeed, mice treated at the lower, but effect-
ive dose of APMS-MB-DOX (0.05 mg/kg) had less aver-
age weight loss than those treated with the high dose
(0.2 mg/kg) of DOX alone (Figure 3). Pair-wise compari-
sons of weight loss rates also showed that the treatment
group receiving the higher dose of DOX (0.2 mg/kg)
had a significantly different slope (*) than other treat-
ment groups. Thus, mice receiving a high dose of DOX
alone lost significantly more weight over time in contrast
to mice receiving a lower non-effective dose of DOX
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(0.05 mg/kg). These results suggest that an effective dose
of APMS-MB-DOX is well tolerated over the duration of
multiple treatments.
Treatment with APMS-MB-DOX (0.05 mg/kg) is associated
with trends toward increased necrosis and significantly
decreased proliferation in spheroid MMs
Gross examination of the tumors and major organs in
the peritoneal cavity following euthanasia revealed that
mice in all groups had MM involvement with the intes-
tine, reproductive organs, stomach, gut, kidney, liver and
spleen (Table 1). Animals treated with DOX high (0.02
mg/kg) or DOX low (0.05 mg/kg) also had bloody PLF.
Bloody PLF was not observed in mice treated with
APMS-MB-DOX (0.05 mg/kg). Given the reduction in
tumor volume, decreased weight loss, and the lack of
bloody PLF in groups treated with APMS-MB-DOX
(0.05 mg/kg) in comparison to the same dose of DOX
alone, APMS-MB or saline controls, we hypothesized
that tumor tissue from these animals would have in-
creased areas of necrosis and fewer proliferating cells.
We stained representative mesenteric and spheroid
(free-floating) tumors [9] from each animal using H&E
staining in the saline, DOX low (0.05 mg/kg) and
APMS-MB-DOX (0.05 mg/kg) treatment groups, and a
board-certified pathologist assessed the tissues to evalu-
ate the average percentage of total tumor area exhibiting
necrosis. Examination of mesenteric tumors revealed
more necrotic tissue in the saline treatment group - an
average of 65% compared to the DOX (0.05 mg/kg)
alone (53%) or APMS-MB-DOX (41%) groups. However,
these trends were not statistically significant. In spheroid
tumors, necrosis was roughly comparable between treat-
ment groups (20-25%) and lower overall (Figure 4A, B).
No significant changes in the percentage of Ki-67-posi-
tive, i.e., proliferating cells, were observed in mesenteric
MMs (Figure 5A-C). However, Ki-67-positive cell stain-
ing in spheroid MMs showed significantly decreased
proliferation in the APMS-MB-DOX (0.05 mg/kg) treat-
ment group when compared to saline controls or mice
receiving a comparable dose of DOX alone (0.05 mg/kg)
(p ≤ 0.05). Histopathology of spheroids showed focal
areas of necrosis in the interiors of these smaller,
ascites-like tumors. Thus APMS-MB-DOX may have a
greater impact on inhibition of proliferation because mi-
croparticles are in the IP milieu and penetrate and ac-
cess the tumor interior more easily [10].
Treatment with APMS-MB-DOX (0.05 mg/kg) causes
significant changes in inflammatory cell profiles in PLF
We have speculated, based on many findings, that
chronic inflammation is a feature of the development and
establishment of MMs [31]. To address this question, andto determine whether or not the treatment regimens used
in these experiments affected immune cell profiles in PLF,
cytospins were evaluated as described previously [9]. PLF
samples from treatment groups receiving effective concen-
trations of APMS-MB-DOX (0.05 mg/kg) or DOX alone
(0.2 mg/kg) contained a significantly higher (p ≤ 0.05)
total number of cells/mL in PLF than mice treated
with DOX (0.05 mg/kg) alone or APMS-MB (Figure 6A).
Differential cell counts revealed that when compared
to the saline group, the percentage of macrophages was
significantly higher in all treatment groups, whereas
numbers of neutrophils were significantly lower (p ≤ 0.05)
(Figure 6B).
HPLC analysis confirms delivery of DOX to tumor tissue
To confirm that the reduction in tumor volume and
weight was due to DOX, we examined levels of DOX in
tumor homogenates in tissues and PLF fluids of
tumor-bearing mice receiving 3× weekly doses of DOX
(0.05 mg/kg) or APMS-MB-DOX (0.05 mg/kg). HPLC
analysis was performed at the end of 3 wks of treatment
(data not shown). We were unable to detect DOX in the
PLF of either treatment group, suggesting it had been
released and already excreted and/or accumulated in
tumor tissue. Supporting the latter hypothesis, DOX
was detected in the tumor tissues of treatment groups
receiving DOX alone (2.47 nmoles/gm of MM tissue) or
APMS-MB-DOX (2.57 nmoles/gm of MM tissue). Though
the amount of DOX was slightly higher in the MMs in the
targeted therapy group, the amounts of DOX were
not significantly different between groups.
Historically in patients receiving DOX for chemother-
apy, cardiotoxicity has been a documented side-effect.
We purposely designed APMS in the micrometer rather
than nano- particle size range so that they would not
enter the vasculature and deliver DOX to the heart.
Moreover, in vivo imaging of Gadolinium-labeled APMS
microparticles in rodents after IP injection using MRI
shows that particles not remaining in the IP space are
cleared via the bladder. In these studies and others, exam-
ination of the hearts of mice by a board-certified path-
ology failed to show any particles or adverse pathology.
Both M1 and M2 tumor-associated macrophages (TAMs)
occur in MMs
MMs are historically associated with areas of inflamma-
tion in both animal models and human tissues, and
TAMs also are a prominent feature of our SCID mouse
model [10]. In studies here, our objective was to deter-
mine if TAMs in MMs reflected M1 (anti-tumor) and/or
M2 (pro-tumor) phenotypes. In both untreated (saline)
and APMS-MB mice, M2 (green) TAMs appeared to
predominate (Figure 7), but M1 TAMs (red) were noted
in discrete surface accumulations along the edges of
Figure 4 Administration of APMS-MB-DOX microparticles (0.05 mg/kg) enhances cell death in spheroid tumors. Paraffin sections
(4 μm thick) of mesenteric and spheroid MM tumors from each animal were stained using H&E. (A) Quantification of the average percent
necrosis (Mean +/- SEM) per area of section was assessed by a board-certified pathologist analyzing 4 fields at 10× magnification. Trends in
mesenteric tumors did not reach statistical significance. (B) Representative images of both mesenteric and spheroid tumors; scale bar represents
100 μM. N = necrotic area.
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Figure 5 Administration of APMS-MB-DOX microparticles (0.05 mg/kg) decreases proliferation in spheroid tumors. (A) Sections were
stained for Ki-67 to assess cell proliferation. Quantification of Ki-67-positive cells per total cells counted from the same tumors (Mean +/- SEM)
was scored by two individuals evaluating 5 regions at 40× magnification and counting 200 cells/region for each tumor section using a blind
coding system. Treatment with APMS-MB-DOX (0.05 mg/kg) significantly decreased Ki-67-positive cells in spheroid MMs compared to saline
controls (*) or groups receiving a comparable dose of DOX alone (†) (p ≤ 0.05). (B) Representative images of tissues stained for Ki-67 (4× objective);
scale bar represents 100 μM. (C) Higher magnification micrographs were acquired with a 40× objective. Scale bar represents 50 μM.
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of tumors. Further quantitative studies are planned in all
treatment groups.
Discussion
Clinical trials that have been conducted or are ongoing
have utilized anti-mesothelin recombinant immunotoxins
(SS1 {dsFv} PE38: Fv portion of antibody SS1 fused totruncated Pseudomonas exotoxin) alone and in com-
bination with chemotherapeutics [32-34], or the anti-
mesothelin antibody MORAb-009 (a chimeric IgG/k/SS1
{dsFv} fusion antibody) leading to an antibody-dependent
cell-mediated cytotoxic response [18,35]. Additionally,
tumor vaccines targeted against mesothelin are currently
being studied. A mesothelin tumor vaccine (CRS-207) is
currently in a phase II trial in combination with the
Figure 6 Effects of treatment on total and differential cell
populations in PLF. (A) Total cells recovered in PLF samples
(Mean +/- SEM) were increased in the APMS-MB-DOX (0.05 mg/kg)
and DOX high (0.2 mg/kg) groups as compared to APMS-MB (†) and
DOX low (0.05 mg/kg) groups (‡) (p ≤ 0.05). (B) All treatments
significantly increased the percentage of total macrophage (MAC)
cells/mL (Mean +/- SEM) and significantly decreased the percentage
of total neutrophils (NEU/mL) compared to saline control groups
(*) (p ≤ 0.05).
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in vitro study has reported the success of a lentivirus-
expressing anti-mesothelin microRNA (MSLNmiR3) that
silences the mesothelin gene (MSLN). This approach
causes a 60% reduction in ovarian cancer cell (OVca429)
viability following infection with (MSLNmiR3) [37].
We show in Figure 2 that APMS-MB-DOX (0.05 mg/kg)
significantly reduces tumor volume compared to untreated
(saline) tumors, whereas free DOX at the same concentra-
tion did not achieve significance in reduction of tumor
volume. We also have previously evaluated in triplicate ex-
periments in this same tumor model, groups of SCID mice
exposed to APMS alone (160 mg/kg), free DOX alone at 3concentrations (0.33, 1 and 5 mg/kg) and APMS-DOX (no
mesothelin-labeling) at 0.33 and 1 mg/kg doses by
Hillegass et al. [26]). Comparison of these results shows
that APMS-MB DOX (0.05 mg/kg) when compared to
APMS- DOX (0.33 mg/kg) is effective therapeutically, even
at > 6-fold lower concentrations. Furthermore, APMS-
MB-DOX (0.05 mg/kg) significantly reduced tumor vol-
ume and weight when compared to mice treated with only
APMS-MB. We have shown here that with the targeting
abilities of APMS-MB-DOX, we can achieve similar de-
creases in tumor volume and weight reduction by using
only 1/4 of the DOX dose (0.05 mg/kg) when compared to
saline controls. These findings demonstrate that enhanced
delivery of DOX via APMS-MB microparticles is causing
enhanced efficacy rather than an immune response trig-
gered by the presence of the MB [20]. This conclusion is
further supported by the specific detection of DOX in
tumor tissues by HPLC. These encouraging results at low
doses of DOX highlight the need for future experiments
that could examine the efficacy of multiple doses of
APMS-MB-DOX. APMS-MB may also be used to deliver
other chemotherapeutic drugs such as Alimta and the
combination of cisplatin/carboplatin, the gold standard in
chemotherapeutic treatment of MM.
In addition to the decreases in tumor volume and
weight observed using APMS-MB-DOX microparticles,
the animals in this group lost less body weight than mice
treated with effective doses of high DOX (0.2 mg/kg)
alone. Mice receiving APMS-MB-DOX were also less
lethargic and maintained normal activity and grooming
behavior when compared to mice treated with DOX alone
at either high or low doses. Thus studies here suggest that
local administration of lower doses of therapeutic drugs or
macromolecules [12] that can be encapsulated in APMS is
an effective method to circumvent toxicities associated
with systemic administration of agents [26]. Local admin-
istration of hyperthermic chemoperfusion [6,7,38-41] is a
treatment regimen for patients with diffuse peritoneal or
pleural MM, thus it is feasible to perfuse drug-loaded
APMS into the pleural or peritoneal cavities.
Histochemical analysis of tumor tissue from the saline,
low DOX (0.05 mg/kg) alone and APMS-MB-DOX (0.05
mg/kg) treatment groups was performed on both mesen-
teric and spheroid tumors to evaluate the mechanisms
of tumor shrinkage in the latter group. Treatment with
APMS-MB-DOX (0.05 mg/kg) caused significant de-
creases in cell proliferation, as evaluated by Ki-67 stain-
ing, in spheroid tumors. It was also noted that in both
mesenteric and spheroid tumors treated with targeted
APMS-MB-DOX, areas of necrosis had a more diffuse
cellular pattern compared to the very discrete and more
centralized areas of necrosis seen in other treatment
groups (see Figure 4B). This appears to reflect infiltra-
tion of cells of the immune system, such as tumor
Figure 7 Localization of M1 and M2 tumor-associated macrophages (TAMs) in tumors. (A) Tiled images from saline (untreated) MM.
(B) Higher magnification of the surface of a saline (untreated) MM. (C) Interior of a saline (untreated) MM. (D) Tiled image of a MM treated with
APMS-MB. (E) Higher magnification of the surface of APMS-MB-treated MM. (F) Interior of an APMS-MB-treated MM. Note that nuclei are stained
blue, M1 TAMs are red, and M2 TAMs are green. White scale bars in A and D are 100 μM and in B, C, E and F are 50 μM.
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or M2 (pro-tumor) phenotype, which may modulate
tumor cell death. We have previously noted large num-
bers of TAMs in both spheroid and mesenteric MMs
[10], and these data are supported by photomicrographs
of M1 and M2 macrophages in MMs and increased
macrophages observed in PLF fluids as reported here.TAMs have been shown to play a very important role in
tumor cell invasion, proliferation, survival, angiogenesis,
and immune suppression [42,43]. While macrophages
from normal tissue are capable of presenting tumor anti-
gens, lysing tumor cells, activating the anti-tumor func-
tions as well as activating T cells and natural killer cells,
TAMs in solid tumors may lack these functions. Moreover,
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further modification of function and or modulation/
suppression of immunostimulatory cytokines [44]. The
decreases in neutrophils seen in PLF in all treatment
groups suggest that increased numbers of macrophages
localized to tumors causes TAMs to assume an immuno-
suppressive phenotype and suppress the infiltration of
neutrophils [45].
We also have observed that mesenteric tumors recov-
ered from saline-treated mice tend to have larger areas
of necrosis at their centers, and we hypothesize that this
may be due to the hypoxic microenvironment existing
deeper in the tissue that is typical of solid tumors
[46,47]. This may explain why trends towards necrosis
are greater in untreated animals as these tumors are
generally larger (data not shown). The most striking ef-
fect of APMS-MB-DOX is observed in smaller spheroids
where the extracellular matrix and tumor vasculature
are most likely developing at the time of treatment [48].
Since solid tumors are a dynamic system, the compos-
ition and architecture of the tissue, the binding of drugs
to cellular components, and changes in tumor cell
density over time may all play a role in the effect of a
given therapy on developing tumors [49]. Spheroid MMs
treated with APMS-MB-DOX contained significantly
lower percentages of proliferating cells compared to
either saline-treated controls or groups after treatment
with DOX alone at the same dose. This may reflect the
fact that APMS are able to penetrate tumor tissue and
traverse to the interior of the tumor mass over time. In
support of this concept, APMS-MB persist both extra-
cellularly and intracellularly in tumor cells and macro-
phages in PLF [10].
In our IP model of MM, neutropenia and increases in
macrophages in PLF correlate with tumor growth over
time [9]. Using this model, we have also characterized
time-dependent patterns of inflammation and tumor de-
velopment using multiple MM cell lines. Several known
growth factors for MMs including Vascular Endothelial
Growth Factor (VEGF), Granulocyte Colony Stimulating
Factor (G-CSF), basic Fibroblast Growth Factor (bFGF),
and Platelet Derived Growth Factor (PDGF-BB) are sig-
nificantly elevated (p ≤ 0.05) in PLF before development
of MMs [9]. It is possible that APMS-MB-DOX via dir-
ect interactions between MB and these proteins inhibits
their expression or activity, thus decreasing cell prolifer-
ation. Thus, MB alone might be potentially inactivating
gene or protein expression of chemokines or cytokines,
avenues which are presently being explored.
Conclusions
In conclusion, we demonstrate here that use of targeted mi-
croparticles (APMS-MB-DOX) (0.05 mg/kg) is an effective
therapeutic strategy that is superior to treatment with equalamounts of DOX (0.05 mg/kg) alone and decreases the
detrimental side-effects of systemic administration of
DOX (0.2 mg/kg) alone. Using this targeting approach,
effective doses of DOX can be reduced approximately
4-fold without any side effects or toxicity. Since APMS-
MB-DOX (0.05 mg/kg) has the potential to decrease the
number of proliferating tumor cells in developing MM
spheroids, this approach also may be useful when pre-
malignant or malignant MM cells are first seen in periton-
eal or pleural fluids, i.e., before histopathological diagnosis
of MMs.
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